Review

wtap proteintech (Proteintech)

Name: wtap proteintech
Brand: Proteintech
Rating: 96 (195 reviews)

Proteintech is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Proteintech wtap proteintech
Wtap Proteintech, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 195 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/wtap proteintech/product/Proteintech
Average 96 stars, based on 195 article reviews

wtap proteintech - by Bioz Stars, 2026-02

96/100 stars

Images

Image Search Results

The role of WTAP in hepatic steatosis in vivo by AAV8 tail vein injection . A) Schematic diagram of study design using the AAV8-WTAP injection to mimic the overexpression of WTAP in C57BL/6 mice, n = 5 per group; B) Western blotting of WTAP expression in C57/BL6 mice treated with AAV8-WTAP or AAV8-Blank. n = 5 per group; C) Representative images of the gross appearance in the liver histology (1 cm), quantification of the liver index (%), H&E (100 μm), F4/80 antibody (100 μm), Masson staining (100 μm), and ORO staining (100 μm); D-I) Serum concentration of ALT (U/L) (D), AST (U/L) (E), triglyceride (mg/dL) (F), cholesterol (mg/dL) (G), LDL (mg/dL) (H), and HDL (mg/dl) (I) in C57/BL6 mice treated with AAV8-WTAP or AAV8-Blank. n = 5 per group; J) Representative quantitative PCR analysis with key genes involved in lipogenesis, FAO and OXPHOS metabolism in C57/BL6 mice treated with AAV8-WTAP or AAV8-Blank. n = 5 per group; K) Schematic diagram of study design using AAV8-shWTAP to mimic the inhibition of WTAP in C57BL/6 mice; L) Western blotting of WTAP expression in C57/BL6 mice treated with AAV8-shWTAP, AAV8-shWTAP + H. pylori SS1 infection, AAV8-shBlank, and AAV8-shWTAP + H. pylori infection. n = 5 per group; M) Representative images of the gross appearance in the liver histology (1 cm), quantification of the liver index (%), H&E (100 μm), F4/80 antibody (100 μm), Masson staining (100 μm), and oil red staining (100 μm). N -Q) Serum concentration of ALT (U/L) ( N ), AST (U/L) (O), triglyceride (mmol/L) ( P ), and cholesterol (mmol/L) (Q) in C57/BL6 mice treated with AAV8-shWTAP, AAV8-shWTAP + H. pylori SS1 infection, AAV8-shBlank, and AAV8-shWTAP + H. pylori infection. n = 5 per group. Statistical analysis was performed using Two-tailed Student's t -test (two groups) and one-way analysis of variance (ANOVA) (multiple groups) followed by Bonferroni's test. *p < 0.05; **p < 0.01; and ***p < 0.001 .

Journal: Gut Microbes

Article Title: Helicobacter pylori infection aggravates hepatic steatosis by lactylation-driven WTAP-mediated m 6 A modification

doi: 10.1080/19490976.2025.2599543

Figure Lengend Snippet: The role of WTAP in hepatic steatosis in vivo by AAV8 tail vein injection . A) Schematic diagram of study design using the AAV8-WTAP injection to mimic the overexpression of WTAP in C57BL/6 mice, n = 5 per group; B) Western blotting of WTAP expression in C57/BL6 mice treated with AAV8-WTAP or AAV8-Blank. n = 5 per group; C) Representative images of the gross appearance in the liver histology (1 cm), quantification of the liver index (%), H&E (100 μm), F4/80 antibody (100 μm), Masson staining (100 μm), and ORO staining (100 μm); D-I) Serum concentration of ALT (U/L) (D), AST (U/L) (E), triglyceride (mg/dL) (F), cholesterol (mg/dL) (G), LDL (mg/dL) (H), and HDL (mg/dl) (I) in C57/BL6 mice treated with AAV8-WTAP or AAV8-Blank. n = 5 per group; J) Representative quantitative PCR analysis with key genes involved in lipogenesis, FAO and OXPHOS metabolism in C57/BL6 mice treated with AAV8-WTAP or AAV8-Blank. n = 5 per group; K) Schematic diagram of study design using AAV8-shWTAP to mimic the inhibition of WTAP in C57BL/6 mice; L) Western blotting of WTAP expression in C57/BL6 mice treated with AAV8-shWTAP, AAV8-shWTAP + H. pylori SS1 infection, AAV8-shBlank, and AAV8-shWTAP + H. pylori infection. n = 5 per group; M) Representative images of the gross appearance in the liver histology (1 cm), quantification of the liver index (%), H&E (100 μm), F4/80 antibody (100 μm), Masson staining (100 μm), and oil red staining (100 μm). N -Q) Serum concentration of ALT (U/L) ( N ), AST (U/L) (O), triglyceride (mmol/L) ( P ), and cholesterol (mmol/L) (Q) in C57/BL6 mice treated with AAV8-shWTAP, AAV8-shWTAP + H. pylori SS1 infection, AAV8-shBlank, and AAV8-shWTAP + H. pylori infection. n = 5 per group. Statistical analysis was performed using Two-tailed Student's t -test (two groups) and one-way analysis of variance (ANOVA) (multiple groups) followed by Bonferroni's test. *p < 0.05; **p < 0.01; and ***p < 0.001 .

Article Snippet: Samples were then incubated with primary antibodies, including anti-F4/80 antibodies (Servicebio, GB113373 ; 1:200), anti-WTAP antibodies (Proteintech, 10200-1-AP; 1:200), anti-H3K18la-antibodies (PTM-bio, PTM-1427RM; 1:200), anti-Pan-Kla-antibodies (PTM-bio, PTM-1401RM; 1:200) overnight at 4 °C.

Techniques: In Vivo, Injection, Over Expression, Western Blot, Expressing, Staining, Concentration Assay, Real-time Polymerase Chain Reaction, Inhibition, Infection, Two Tailed Test

H. pylori infection promotes glycolysis and regulates WTAP expression via histone lactylation . A) Volcano plot of significantly-changed metabolites and KEGG analysis of remarkably changed pathways from untargeted metabolomics analysis; B) Lactic acid level of liver tissues in C57BL/6 mice with or without H. pylori SS1 infection, n = 5 per group; C) The glycolytic capability of HepG2 cells co-cultured with or without H. pylori OMVs using ECAR curve, n = 3 per group; D) Mitochondrial oxidative capacity was measured after HepG2 cells co-cultured with or without H. pylori OMVs using OCR curve, n = 3 per group; E) Intracellular ROS levels of HepG2 cells co-cultured with or without H. pylori 26695 OMVs in a dose or time-dependent manner, n = 3 per group; F-G) mRNA and protein expression of LDHA and LDHB in liver tissues or HepG2 cells following H. pylori 26695 infection using qRT-PCR (F) and Western blot (G) analysis, n = 3 per group. H) mRNA and protein expression of WTAP in HepG2 cells after lactate treatment, n = 3 per group; I) Representative images of Silver staining-MS of lactylated proteins; J) Pan-lysine lactylation levels in cells were measured at indicated times with 10 ug/ml H. pylori 26695 OMVs or after the indicated dose treatment for 24 h and lysine lactylation levels of H3 were detected under the same conditions. K) ChIP-qPCR using anti-H3K18la antibodies validates H3K18la enrichment in peak 1 and peak 2 within the promoter region of WTAP in HepG2. L) WTAP mRNA and protein level after 2-DG and oxamate treatment, n = 3 per group. M) ChIP-qPCR using anti-H3K18la antibodies validates H3K18la enrichment in HepG2 cells after 2-DG or oxamate treatment or si-LDHA/B transfection. N ) WTAP mRNA and protein level in HepG2 cells after si-LDHA/B transfection with or without Nala addition, n = 3 per group. Statistical analysis was performed using Two-tailed Student's t -test (two groups) and one-way analysis of variance (ANOVA) (multiple groups) followed by Bonferroni's test. *p < 0.05; **p < 0.01; and ***p < 0.001 .

Journal: Gut Microbes

Article Title: Helicobacter pylori infection aggravates hepatic steatosis by lactylation-driven WTAP-mediated m 6 A modification

doi: 10.1080/19490976.2025.2599543

Figure Lengend Snippet: H. pylori infection promotes glycolysis and regulates WTAP expression via histone lactylation . A) Volcano plot of significantly-changed metabolites and KEGG analysis of remarkably changed pathways from untargeted metabolomics analysis; B) Lactic acid level of liver tissues in C57BL/6 mice with or without H. pylori SS1 infection, n = 5 per group; C) The glycolytic capability of HepG2 cells co-cultured with or without H. pylori OMVs using ECAR curve, n = 3 per group; D) Mitochondrial oxidative capacity was measured after HepG2 cells co-cultured with or without H. pylori OMVs using OCR curve, n = 3 per group; E) Intracellular ROS levels of HepG2 cells co-cultured with or without H. pylori 26695 OMVs in a dose or time-dependent manner, n = 3 per group; F-G) mRNA and protein expression of LDHA and LDHB in liver tissues or HepG2 cells following H. pylori 26695 infection using qRT-PCR (F) and Western blot (G) analysis, n = 3 per group. H) mRNA and protein expression of WTAP in HepG2 cells after lactate treatment, n = 3 per group; I) Representative images of Silver staining-MS of lactylated proteins; J) Pan-lysine lactylation levels in cells were measured at indicated times with 10 ug/ml H. pylori 26695 OMVs or after the indicated dose treatment for 24 h and lysine lactylation levels of H3 were detected under the same conditions. K) ChIP-qPCR using anti-H3K18la antibodies validates H3K18la enrichment in peak 1 and peak 2 within the promoter region of WTAP in HepG2. L) WTAP mRNA and protein level after 2-DG and oxamate treatment, n = 3 per group. M) ChIP-qPCR using anti-H3K18la antibodies validates H3K18la enrichment in HepG2 cells after 2-DG or oxamate treatment or si-LDHA/B transfection. N ) WTAP mRNA and protein level in HepG2 cells after si-LDHA/B transfection with or without Nala addition, n = 3 per group. Statistical analysis was performed using Two-tailed Student's t -test (two groups) and one-way analysis of variance (ANOVA) (multiple groups) followed by Bonferroni's test. *p < 0.05; **p < 0.01; and ***p < 0.001 .

Techniques: Infection, Expressing, Cell Culture, Quantitative RT-PCR, Western Blot, Silver Staining, ChIP-qPCR, Transfection, Two Tailed Test

$Direct lactylation of WTAP enhanced the capture of m6A-modified RNA. A) MOE is used to predict the binding affinity between the WTAP protein and L-lactate; B) Illustration of WTAP Kla sites derived from HepG2 cells identified by LC-MS; C) Lactylation of WTAP in 293 T cells was confirmed by IP method. 293 T cells transfected with FLAG-WTAP, treated with ddH2O or 25 mM L-lactic acid for 24 h. The cells were lysed for SDS pre-treated immunoprecipitation with anti-FLAG antibody followed by western blotting; D) Lactylation of WTAP in HepG2 was confirmed by IP method. HepG2 co-cultured with OMVs or treated with 25 mM LA for 24 h. The cells were lysed for SDS pre-treated immunoprecipitation with anti-METTL3 antibody followed by western blotting; E) FLAG-WTAP, with Myc-METTL3 or Myc-METTL14 were transfected into 293 T cells for 24 h. Then cells were treated with 25 mM L-lactic acid for 24 h. Lysates were used for IP with anti-FLAG antibody, followed by western blotting; F) FLAG-WTAP, with Myc-METTL3 or Myc-METTL14 were transfected into 293 T cells for 24 h. Then cells were treated with 25 mM L-lactic acid for 24 h. Cells were harvested for immunofluorescence staining and further photographed by laser scanning confocal microscopy. Scale bars, 20 mm; G) HepG2 were treated with 25 mM L-lactic acid for 24 h. Cells were harvested for immunofluorescence staining (20 mm) and further photographed by laser scanning confocal microscopy; H) Western blotting analysis of the distribution in nuclear and cytoplasmic fractions of WTAP in HepG2 treated with or without 25 mM L-lactic acid for 24 h. I) Western blotting analysis of WTAP in HepG2 with or without lactic acid treated with 0.1 mg/mL CHX for indicated time; J) FLAG-WTAP was transfected into 293 T cells for 24 h. Then cells were treated with L-lactic acid or Nala for 24 h. Cells were 254 nm UV-crosslinked before harvesting. Lysates were used for SDS pre-treated immunoprecipitation with anti-FLAG antibody, followed by western blotting to detect indicated targets. K) FLAG-WTAP (WT), FLAG-WTAP (K99R), FLAG-WTAP (K134R), and FLAG-WTAP (K99R and K134R) were transfected into 293 T cells for 24 h. Then cells were treated with L-lactic acid for 24 h. Cells were 254 nm UV-crosslinked before harvesting. Lysates were used for SDS pre-treated immunoprecipitation with anti-FLAG antibody, followed by western blotting to detect indicated targets; L) Western blotting analysis of WTAP in 293 T cells transfected with FLAG-WTAP (WT) and FLAG-WTAP (K99R and K134R) with or without lactic acid treated with 0.1 mg/mL CHX for indicated time.$

Journal: Gut Microbes

Article Title: Helicobacter pylori infection aggravates hepatic steatosis by lactylation-driven WTAP-mediated m 6 A modification

doi: 10.1080/19490976.2025.2599543

Figure Lengend Snippet: Direct lactylation of WTAP enhanced the capture of m6A-modified RNA. A) MOE is used to predict the binding affinity between the WTAP protein and L-lactate; B) Illustration of WTAP Kla sites derived from HepG2 cells identified by LC-MS; C) Lactylation of WTAP in 293 T cells was confirmed by IP method. 293 T cells transfected with FLAG-WTAP, treated with ddH2O or 25 mM L-lactic acid for 24 h. The cells were lysed for SDS pre-treated immunoprecipitation with anti-FLAG antibody followed by western blotting; D) Lactylation of WTAP in HepG2 was confirmed by IP method. HepG2 co-cultured with OMVs or treated with 25 mM LA for 24 h. The cells were lysed for SDS pre-treated immunoprecipitation with anti-METTL3 antibody followed by western blotting; E) FLAG-WTAP, with Myc-METTL3 or Myc-METTL14 were transfected into 293 T cells for 24 h. Then cells were treated with 25 mM L-lactic acid for 24 h. Lysates were used for IP with anti-FLAG antibody, followed by western blotting; F) FLAG-WTAP, with Myc-METTL3 or Myc-METTL14 were transfected into 293 T cells for 24 h. Then cells were treated with 25 mM L-lactic acid for 24 h. Cells were harvested for immunofluorescence staining and further photographed by laser scanning confocal microscopy. Scale bars, 20 mm; G) HepG2 were treated with 25 mM L-lactic acid for 24 h. Cells were harvested for immunofluorescence staining (20 mm) and further photographed by laser scanning confocal microscopy; H) Western blotting analysis of the distribution in nuclear and cytoplasmic fractions of WTAP in HepG2 treated with or without 25 mM L-lactic acid for 24 h. I) Western blotting analysis of WTAP in HepG2 with or without lactic acid treated with 0.1 mg/mL CHX for indicated time; J) FLAG-WTAP was transfected into 293 T cells for 24 h. Then cells were treated with L-lactic acid or Nala for 24 h. Cells were 254 nm UV-crosslinked before harvesting. Lysates were used for SDS pre-treated immunoprecipitation with anti-FLAG antibody, followed by western blotting to detect indicated targets. K) FLAG-WTAP (WT), FLAG-WTAP (K99R), FLAG-WTAP (K134R), and FLAG-WTAP (K99R and K134R) were transfected into 293 T cells for 24 h. Then cells were treated with L-lactic acid for 24 h. Cells were 254 nm UV-crosslinked before harvesting. Lysates were used for SDS pre-treated immunoprecipitation with anti-FLAG antibody, followed by western blotting to detect indicated targets; L) Western blotting analysis of WTAP in 293 T cells transfected with FLAG-WTAP (WT) and FLAG-WTAP (K99R and K134R) with or without lactic acid treated with 0.1 mg/mL CHX for indicated time.

Techniques: Modification, Binding Assay, Derivative Assay, Liquid Chromatography with Mass Spectroscopy, Transfection, Immunoprecipitation, Western Blot, Cell Culture, Immunofluorescence, Staining, Confocal Microscopy

H. pylori- induced hepatic steatosis in HFDHP mice is alleviated after H. pylori eradication. A) Schematic diagram of the animal experiment; C57BL/6 mice with HFD diets were divided into HFDHP ( H. pylori SS1 infection) and HFDHPe ( H. pylori eradication) groups; n = 5 per group; B−F) Serum concentration of glucose (mg/dL) (B), insulin (pg/mL) (C), triglyceride (mg/dL) (D), cholesterol (mg/dL) (E), and LDL (mg/dL) (F) in H. pylori -infected C57/BL6 mice eradicated with triple therapy or placebo. n = 5 per group; G) Representative images of the gross appearance in the liver histology (1 cm), quantification of the liver index (%), H&E (100μm), F4/80 antibody (100μm), Masson staining (100μm), and ORO staining (100μm). Histogram plots of weight (g), liver index (%), average liver balloon diameters (μm), number of F4/80 positive cells (%), CVF (%), and oil red lipid contents (%) of H. pylori -infected C57/BL6 mice eradicated with triple therapy or placebo. n = 5 per group; H) Representative quantitative PCR analysis with key genes involved in lipogenesis, FAO and OXPHOS metabolism in H. pylori -infected C57/BL6 mice eradicated with triple therapy or placebo. n = 5 per group; I−J) Immunofluorescence staining of Pan-Kla (I) and H3k18la (J) expression in H. pylori -infected C57/BL6 mice eradicated with triple therapy or placebo. n = 5 per group; K) Western blotting of WTAP and GLUT3 expression in H. pylori -infected C57/BL6 mice eradicated with triple therapy or placebo. n = 5 per group. Statistical analysis was performed using Two-tailed Student's t -test. *p < 0.05; **p < 0.01; and ***p < 0.001 .

Journal: Gut Microbes

Article Title: Helicobacter pylori infection aggravates hepatic steatosis by lactylation-driven WTAP-mediated m 6 A modification

doi: 10.1080/19490976.2025.2599543

Figure Lengend Snippet: H. pylori- induced hepatic steatosis in HFDHP mice is alleviated after H. pylori eradication. A) Schematic diagram of the animal experiment; C57BL/6 mice with HFD diets were divided into HFDHP ( H. pylori SS1 infection) and HFDHPe ( H. pylori eradication) groups; n = 5 per group; B−F) Serum concentration of glucose (mg/dL) (B), insulin (pg/mL) (C), triglyceride (mg/dL) (D), cholesterol (mg/dL) (E), and LDL (mg/dL) (F) in H. pylori -infected C57/BL6 mice eradicated with triple therapy or placebo. n = 5 per group; G) Representative images of the gross appearance in the liver histology (1 cm), quantification of the liver index (%), H&E (100μm), F4/80 antibody (100μm), Masson staining (100μm), and ORO staining (100μm). Histogram plots of weight (g), liver index (%), average liver balloon diameters (μm), number of F4/80 positive cells (%), CVF (%), and oil red lipid contents (%) of H. pylori -infected C57/BL6 mice eradicated with triple therapy or placebo. n = 5 per group; H) Representative quantitative PCR analysis with key genes involved in lipogenesis, FAO and OXPHOS metabolism in H. pylori -infected C57/BL6 mice eradicated with triple therapy or placebo. n = 5 per group; I−J) Immunofluorescence staining of Pan-Kla (I) and H3k18la (J) expression in H. pylori -infected C57/BL6 mice eradicated with triple therapy or placebo. n = 5 per group; K) Western blotting of WTAP and GLUT3 expression in H. pylori -infected C57/BL6 mice eradicated with triple therapy or placebo. n = 5 per group. Statistical analysis was performed using Two-tailed Student's t -test. *p < 0.05; **p < 0.01; and ***p < 0.001 .

Techniques: Infection, Concentration Assay, Staining, Real-time Polymerase Chain Reaction, Immunofluorescence, Expressing, Western Blot, Two Tailed Test

Review

Structured Review

Images

Similar Products

Image Search Results